Nachrichten zur Royalty Pharma PLC Aktie

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

…

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade

This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500…

Royalty Pharma: Massive Opportunity Ahead

…

Royalty Pharma Reports Third Quarter 2024 Results

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Declares Fourth Quarter 2024 Dividend

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Brain Biotech und der 128-Millionen-Euro-Deal - der "Big Deal" hat sein "Kleingedrucktes"

Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…

EQS-Adhoc: BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab (deutsch)

BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

…

Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript

…

Royalty Pharma Declares Third Quarter 2024 Dividend

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…

Royalty Pharma plc (NASDAQ:RPRX) Stocks Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…

Earnings call: Royalty Pharma reports robust growth and strategic acquisitions By Investing.com

Earnings call: Royalty Pharma reports robust growth and strategic acquisitions…

Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript

…

Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will…

Royalty Pharma Declares Second Quarter 2024 Dividend

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma: Solid Operational Performance

…

Earnings call: Royalty Pharma reports solid growth and portfolio expansion By Investing.com

Earnings call: Royalty Pharma reports solid growth and portfolio expansion…

Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript

…

Royalty Pharma plc 2023 Q4 - Results - Earnings Call Presentation

…

Royalty Pharma Reports Q4 and Full Year 2023 Results

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma: One Of The Best Names In Pharmaceuticals

…

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is…

Royalty Pharma ownership shows strong institutional and insider confidence By Investing.com

Royalty Pharma ownership shows strong institutional and insider confidence…

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop…

Teva signs $125m deal with Royalty Pharma on antipsychotic drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to…

Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript

…

Royalty Pharma Reports Third Quarter 2023 Results

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma to pay $1 billion for Roches SMA drug royalties By Reuters

Royalty Pharma to pay $1 billion for Roches SMA drug royalties…

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with…

Royalty Pharma declares $0.20 dividend

…

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of…

Royalty Pharma In $500 Million Royalty Pact for Gene Therapy Adstiladrin

Royalty Pharma In $500 Million Royalty Pact for Gene Therapy Adstiladrin...…

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…

dpa-AFX ProFeed